Lipocine Inc. (LPCN) — Inside-Filings

Kritische 8-K Meldungen

Datum	Meldung	Schwere	Filing	Auszug
15.12.2025	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;

Stammdaten

Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis; LPCN 1111, an oral prodrug of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the management of decompensated cirrhosis; LPCN 1154, an investigational new drug application to conduct a Phase 2 study in Postpartum depression; LPCN 2101 for women with epilepsy, which has completed pre-clinical study; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.

Unternehmen & Branche

Name	Lipocine Inc.
Ticker	LPCN
CIK	0001535955
Boerse	US
Sektor	Healthcare
Industrie	Biotechnology
SIC	2834 · Pharmaceutical Preparations

Wertpapier & Kennzahlen

CUSIP	–
ISIN	–
Typ	Common Stock
Marktkapitalisierung	12,5 Mio. USD
Beta	1,09
Dividendenrendite	0,00 %

Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »

Finanzkennzahlen (SEC XBRL)

Periode	Filing	Umsatz	Nettoergebnis	EPS	Aktiva	Eigenkapital
2025-12-31	10-K	1,976,677	-9,627,505	-1.69	17,005,612	14,477,416
2025-09-30	10-Q	114,574	-3,186,832	-0.59	16,073,167	14,142,048
2025-06-30	10-Q	622,849	-2,205,716	-0.41	18,577,193	17,128,420
2025-03-31	10-Q	93,864	-1,864,873	-0.35	20,499,726	19,200,077
2024-12-31	10-K	11,198,144	8,352		22,510,501	20,997,565
2024-09-30	10-Q	7,706,738	-2,218,818	-0.44	20,698,318	19,117,100
2024-06-30	10-Q	89,565	-3,068,634	-0.56	23,032,306	21,208,363
2024-03-31	10-Q	7,617,174	3,513,621	0.66	25,446,555	23,956,407
2023-12-31	10-K	-2,850,818	-16,352,082	-3.14	23,001,072	20,369,443
2023-09-30	10-Q	-3,121,996	-6,650,970	-1.27	24,752,343	22,481,522
2023-06-30	10-Q	54,990	-3,548,629	-0.68	30,483,460	28,552,011
2023-03-31	10-Q	54,990	-3,870,230	-0.76	34,021,852	31,960,028
2022-12-31	10-K	500,000	-10,758,636	-2.15	37,542,922	35,634,940
2022-09-30	10-Q	500,000	-2,409,165	-0.52	39,424,228	37,648,823
2022-06-30	10-Q	500,000	-2,631,777	-0.61	42,193,389	39,889,745
2022-03-31	10-Q		-3,487,781	-0.04	47,603,591	42,409,853
2021-12-31	10-K	16,140,838	-634,399	-0.01	52,482,439	45,570,018
2021-09-30	10-Q	54,994	-3,081,297	-0.04	40,389,109	32,811,088
2021-06-30	10-Q		-6,809,041	-0.08	47,179,273	35,745,553
2021-03-31	10-Q		-3,368,082	-0.04	50,576,621	42,390,849

Fondsaktivität (Vorquartalsvergleich)

Keine Fondsdaten für dieses Unternehmen vorhanden.

Insider-Transaktionen (12 Monate)

Datum	Insider	Rolle	Typ	Stückzahl	Kurs	Wert (USD)	Δ
2026-04-07	Higuchi John W.	Director	Open Market Purchase	40,000	2.03	81,200.00	+63,4%
2026-04-06	Patel Mahesh V.	Director, Officer, Chief Executive Officer	Open Market Purchase	25,000	2.03	50,750.00	+39,6%
2026-04-06	Higuchi John W.	Director	Open Market Purchase	123,000	2.05	252,150.00	+196,9%

Top-Fondshalter

Keine Fondsdaten zu dieser Aktie vorhanden.